Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Early gene expression changes in peripheral blood leukocytes with rush immunotherapy

ABSTRACT: Peripheral blood mononuclear cells (PBMC) were collected from ficoll gradients of whole blood and immediately processed for total RNA and stored at -80oC until use. Blood was from allergic patients at different timepoints pre or post immunotherapy (RIT). Gene expression was compared for the different timepoints. Blood samples were collected from allergic patients before or after rush immunotherapy (RIT), total RNA was prepared and gene expression assessed by Illumina. Samples were collected pre-rush or at 1 week, 7 weeks, 4 months (and for one patient 5 months) after beginning rush immunotherapy. Blood was taken at each timepoint prior to the patient receiving immunotherapy at each timepoint.

ORGANISM(S): Homo sapiens

SUBMITTER: Laurie Davis

PROVIDER: E-GEOD-29521 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Similar Datasets

Project description:Interventions: This is a prospective study involving the collection of blood samples for the purposes of measuring circulating tumour DNA from two distinct cohorts of patients: COHORT A: Patients with curatively resected stage II colon cancer- subgroups will be enrolled according to whether adjuvant chemotherapy is recommended by patient’s treating oncologist. Group A - Chemotherpay; Group B - No Chemo (serial blood collection) and Group C - No chemotherapy (baseline sample). Timepoints for each group in COHORT A are as follows: Group A - 60mls of blood will be collected at 11 timepoints- Timepoint 1 - Baseline (4-8 weeks post operation) Timepoint 2 - Post 3 month of chemotherapy Timepoint 3 - Completion of chemotherapy Timepoint (4 - 11) -3 monthly follow ups post completion of treatment (3mths; 6mths; 9mths; 12mths; 15mths; 18 mths; 21 mnths and 24mths) Group B - 60mls of blood will be collected at 9 timepoints - Timepoint 1 - Baseline (4-8 weeks post operation) Timepoint (2 - 9) -3 monthly follow ups post completion of treatment (3mths; 6mths; 9mths; 12mths; 15mths; 18 mths; 21 mnths and 24mths) Group C - 60mls of blood will be collected at 1 timepoint - Timepoint 1 Baseline (4-8 weeks post operation) COHORT B - Patients with metastatic (stage IV) colorectal cancer undergoing first line chemotherapy. 60 mls of blood will be collected at 3 timepoints - Timepoint 1 - Priot to Cycle 1 Day 1 chemotherapy Timepoint 2 - Cycle 1 Day 3 chemotherapy Timepoint 3 - Cycle 2 Day 1 cemotherapy Primary outcome(s): COHORT A Stage II Colrectal Cancer - to demonstrate that persistence of tumour derived DNA in peripheral blood following complete resection of the primary tumour is a sensitive and specific arker of subsequent disease recurrence.[COHORT A - At the completion of the analysis of blood, plasma and tissue samples. COHORT A are as follows: Group A - 60mls of blood will be collected at 11 timepoints- Timepoint 1 - Baseline (4-8 weeks post operation) Timepoint 2 - Post 3 month of chemotherapy Timepoint 3 - Completion of chemotherapy Timepoint (4 - 11) -3 monthly follow ups post completion of treatment (3mths; 6mths; 9mths; 12mths; 15mths; 18 mths; 21 mnths and 24mths) Group B - 60mls of blood will be collected at 9 timepoints - Timepoint 1 - Baseline (4-8 weeks post operation) Timepoint (2 - 9) -3 monthly follow ups post completion of treatment (3mths; 6mths; 9mths; 12mths; 15mths; 18 mths; 21 mnths and 24mths) Group C - 60mls of blood will be collected at 1 timepoint - Timepoint 1 Baseline (4-8 weeks post operation)];COHORT B Stage IV Colorectal Cancer - To confirm that early changes in the level of circulating tumour DNA are a sensitive and specific marker of treatment response or resistance.[COHORT B - At the completion of the analysis of blood, plasma and tissue samples. COHORT B - Patients with metastatic (stage IV) colorectal cancer undergoing first line chemotherapy. 60 mls of blood will be collected at 3 timepoints - Timepoint 1 - Priot to Cycle 1 Day 1 chemotherapy Timepoint 2 - Cycle 1 Day 3 chemotherapy Timepoint 3 - Cycle 2 Day 1 cemotherapy] Study Design: Timing: Prospective

Dataset Information

Early gene expression changes in peripheral blood leukocytes with rush immunotherapy

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure